MEDIFAST INC (MED)
Sector: Consumer Staples
2026 Annual Meeting Analysis
MEDIFAST INC · Meeting: May 19, 2026
Directors FOR
2
Directors AGAINST
5
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Mr. Chard has served as CEO and director since 2016, giving him full tenure overlap with Medifast's catastrophic stock decline of -88.9% over three years, which trails the company-disclosed peer group median by 33.4 percentage points — well above the 20-point trigger threshold for companies with negative absolute returns; the 5-year check does not provide relief because MED's 5-year return of -94.6% also underperforms the peer median by 12 percentage points, confirming sustained rather than transient underperformance.
Ms. Geary joined the board in 2023, meaning her tenure is more than 24 months but less than three years, so the trigger is applied proportionally; the underperformance predates her appointment but the stock has continued to deteriorate significantly during her tenure, and the peer-group gap of 33.4 percentage points is severe enough to warrant flagging even for a relatively new director who covers only part of the underperformance period.
Mr. Schlackman has served on the board since 2015 and chairs the Compensation Committee, giving him full overlap with the period of severe stock underperformance; Medifast's 3-year return of -88.9% trails the peer group median by 33.4 percentage points, exceeding the 20-point trigger for companies with negative absolute returns, and the 5-year return of -94.6% trails peers by 12 percentage points, confirming the underperformance is sustained.
Ms. Thomas joined the board in 2019 and serves on the Compensation Committee, giving her meaningful overlap with the company's multi-year stock collapse; the 3-year peer-group underperformance gap of 33.4 percentage points exceeds the 20-point threshold applicable to companies with negative absolute returns, and the 5-year picture similarly shows underperformance, indicating this is not a transient dip.
Mr. Xian has served since 2018 and has full overlap with the period of severe stock underperformance; Medifast's 3-year return of -88.9% trails the company-disclosed peer group median by 33.4 percentage points, well above the 20-point trigger threshold for companies with negative absolute returns, and the 5-year gap does not provide a mitigating long-term track record of adequate performance.
For Analysis
Mr. Kiai is a new nominee who has not previously served on the board, so he is exempt from the TSR trigger under the 24-month new-director exemption; he brings relevant investing, capital allocation, and finance experience through his role as Managing Partner and Chief Investment Officer of Steamboat Capital, and was nominated pursuant to a formal Cooperation Agreement that reflects active shareholder engagement.
Mr. Rose is a new nominee exempt from the TSR trigger as he has not previously served on the board; he brings finance, legal, and risk management expertise through senior roles at Steamboat Capital and prior experience as a CFO and general counsel, and his nomination reflects the same shareholder-driven Cooperation Agreement process as Mr. Kiai.
The TSR trigger fires for all incumbent directors with meaningful tenure based on Medifast's 3-year stock return of -88.9%, which trails the company's own disclosed compensation peer group median by 33.4 percentage points — exceeding the 20-point threshold applicable when absolute returns are negative. The 5-year return of -94.6% trailing peers by 12 percentage points confirms sustained underperformance rather than a temporary trough, so no 5-year mitigant applies. The two new nominees (Kiai and Rose) are exempt as first-time nominees and receive FOR votes; they were nominated through a Cooperation Agreement with activist investor Steamboat Capital, which itself signals shareholder dissatisfaction with the incumbent board.
Say on Pay
✗ AGAINSTCEO
Daniel R. Chard
Total Comp
$5,584,551
Prior Support
59.1%%
The prior year Say-on-Pay vote received only 59.1% support — well below the 70% threshold in our policy — and while the company made some responsive changes (CEO received no bonus, 2026 pay cut 41%), the reported CEO compensation of $5.58 million for 2025 and the continuation of the same peer-underperforming long-term incentive structure mean the core problem has not been fully remediated. Variable pay remains above levels justified by performance: Medifast's 3-year total shareholder return of -88.9% trails the company's own peer group median by 33.4 percentage points, meaning above-median incentive structures are not supported by shareholder outcomes. Additionally, the long-term performance stock awards for the 2025 cycle continue to use a single annual revenue metric rather than multi-year cumulative targets, which shareholders and proxy advisors specifically flagged, and this structural weakness has not yet been fixed for the awards already granted.
Auditor Ratification
✓ FORAuditor
RSM US LLP
Tenure
N/A
Audit Fees
$752,000
Non-Audit Fees
$21,000
Non-audit fees of $21,000 represent approximately 2.8% of audit fees of $752,000, which is well below the 50% threshold that would raise independence concerns; no material restatements are disclosed; and RSM is a large national firm appropriate for a company of Medifast's current size and complexity. Auditor tenure is not disclosed in the filing, so the tenure trigger cannot fire per policy — tenure non-disclosure is noted as a minor negative factor but does not change the vote.
Overall Assessment
This is a ballot dominated by governance accountability concerns: five of seven director nominees receive AGAINST votes due to sustained and severe stock underperformance, with Medifast's 3-year return of -88.9% trailing its own peer group by 33.4 percentage points over a period when most incumbent directors served on the board. The Say-on-Pay vote also receives an AGAINST recommendation given a prior year support level of only 59.1%, a pay-for-performance gap that has not been fully closed, and continued structural weaknesses in the long-term incentive design; the auditor ratification is the sole proposal warranting a FOR vote, as RSM's fee structure raises no independence concerns.
Compensation Peer Group
14 companies disclosed in 2026 proxy filing